Advertisement

International Journal of Clinical Oncology

, Volume 24, Issue 10, pp 1256–1263 | Cite as

Predictors of favorable survival after secondary cytoreductive surgery for recurrent endometrial cancer

  • Ayumi ShikamaEmail author
  • Takeo Minaguchi
  • Wataru Takao
  • Yoshihiko Hosokawa
  • Keiko Nishida
  • Nobutaka Tasaka
  • Azusa Akiyama
  • Manabu Sakurai
  • Hiroyuki Ochi
  • Toyomi Satoh
Original Article
  • 52 Downloads

Abstract

Objective

The selection criteria for secondary cytoreductive surgery (SCS) for recurrent endometrial cancer (EC) remain to be defined. The present study aimed to identify predictors for favorable survival after SCS for the disease.

Methods

We retrospectively reviewed the medical records of 112 patients who relapsed by 2016 among 1052 who were diagnosed with primary EC between 1985 and 2014. Characteristics associated with overall survival (OS) after SCS were identified using univariate and multivariate analyses.

Results

Twenty-nine of the 112 patients who relapsed underwent SCS. Complete resection was achieved in 18 (62%) patients, whose OS after SCS was significantly better than that of patients receiving incomplete resection (68 vs. 20 months; p = 0.001). Endometrioid histology and performance status (PS) 0 were significant and independent factors for a favorable OS (p = 0.005, and 0.049). The OS of patients with both factors was better than patients with one or no factors (median 75, 19 and 4 months; p = 0.001 and 0.00001). The number of predictors was associated with the rate of complete resection (p = 0.001).

Conclusions

Patients with endometrioid histology and PS 0 should be offered SCS for recurrent EC. Prospective trials are warranted to verify this proposal.

Keywords

Secondary cytoreductive surgery Recurrent endometrial cancer Survival 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

10147_2019_1469_MOESM1_ESM.pdf (56 kb)
Supplementary material 1 (PDF 56 kb)
10147_2019_1469_MOESM2_ESM.pdf (100 kb)
Supplementary material 2 (PDF 99 kb)

References

  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386CrossRefGoogle Scholar
  2. 2.
    Fung-Kee-Fung M, Dodge J, Elit L et al (2006) Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol 101(3):520–529CrossRefGoogle Scholar
  3. 3.
    Morris M, Alvarez RD, Kinney WK et al (1996) Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Gynecol Oncol 60(2):288–291CrossRefGoogle Scholar
  4. 4.
    Barakat RR, Goldman NA, Patel DA et al (1999) Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol 75(1):99–102CrossRefGoogle Scholar
  5. 5.
    Scarabelli C, Campagnutta E, Giorda G et al (1998) Maximal cytoreductive surgery as a reasonable therapeutic alternative for recurrent endometrial carcinoma. Gynecol Oncol 70(1):90–93CrossRefGoogle Scholar
  6. 6.
    Campagnutta E, Giorda G, Piero GD et al (2004) Surgical treatment of recurrent endometrial carcinoma. Cancer 100(1):89–96CrossRefGoogle Scholar
  7. 7.
    Bristow RE, Santillan A, Zahurak ML et al (2006) Salvage cytoreductive surgery for recurrent endometrial cancer. Gynecol Oncol 103(1):281–287CrossRefGoogle Scholar
  8. 8.
    Awtrey CS, Cadungog MG, Leitao MM et al (2006) Surgical resection of recurrent endometrial carcinoma. Gynecol Oncol 102(3):480–488CrossRefGoogle Scholar
  9. 9.
    Ren Y, Shan B, Shi D et al (2014) Salvage cytoreductive surgery for patients with recurrent endometrial cancer: a retrospective study. BMC Cancer 14(1):135CrossRefGoogle Scholar
  10. 10.
    Papadia A, Bellati F, Ditto A et al (2015) Surgical treatment of recurrent endometrial cancer: time for a paradigm shift. Ann Surg Oncol 22(13):4204–4210CrossRefGoogle Scholar
  11. 11.
    Turan T, Tasci T, Karalok A et al (2015) Salvage cytoreductive surgery for recurrent endometrial cancer. Int J Gynecol Cancer 25(9):1623–1632CrossRefGoogle Scholar
  12. 12.
    Bricou A, Bendifallah S, Daix-Moreux M et al (2018) A proposal for a classification for recurrent endometrial cancer: analysis of a French multicenter database from the FRANCOGYN Study Group. Int J Gynecol Cancer 28(7):1278–1284CrossRefGoogle Scholar
  13. 13.
    Iwase H, Furukawa S, Hirasawa T et al (2018) The clinical features of recurrent endometrial cancer in Japan: chemotherapy instead of radiotherapy as postoperative adjuvant treatment. Int J Gynecol Cancer 28(8):1616–1623CrossRefGoogle Scholar
  14. 14.
    Barlin JN, Puri I, Bristow RE (2010) Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol 118(1):14–18CrossRefGoogle Scholar
  15. 15.
    Gottwald L, Pluta P, Piekarski J et al (2010) Long-term survival of endometrioid endometrial cancer patients. Arch Med sci 6(6):937–944CrossRefGoogle Scholar
  16. 16.
    Odagiri T, Watari H, Hosaka M et al (2011) Multivariate survival analysis of the patients with recurrent endometrial cancer. J Gynecol Oncol 22(1):3–8CrossRefGoogle Scholar
  17. 17.
    Zang RY, Li ZT, Tang J et al (2004) Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer 100(6):1152–1161CrossRefGoogle Scholar
  18. 18.
    Harter P, Heitz F, du Bois A (2012) Surgery for relapsed ovarian cancer: when should it be offered? Curr Oncol Rep 14(6):539–543CrossRefGoogle Scholar
  19. 19.
    Minaguchi T, Satoh T, Matsumoto K et al (2016) Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers. Int J Clin Oncol 21(3):573–579CrossRefGoogle Scholar
  20. 20.
    Harter P, Sehouli J, Reuss A et al (2011) Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 21(2):289–295CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2019

Authors and Affiliations

  • Ayumi Shikama
    • 1
    Email author
  • Takeo Minaguchi
    • 1
  • Wataru Takao
    • 1
  • Yoshihiko Hosokawa
    • 1
  • Keiko Nishida
    • 1
  • Nobutaka Tasaka
    • 1
  • Azusa Akiyama
    • 1
  • Manabu Sakurai
    • 1
  • Hiroyuki Ochi
    • 1
  • Toyomi Satoh
    • 1
  1. 1.Department of Obstetrics and Gynecology, Faculty of MedicineUniversity of TsukubaTsukubaJapan

Personalised recommendations